These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. A role for olestra in body weight management. Eldridge AL; Cooper DA; Peters JC Obes Rev; 2002 Feb; 3(1):17-25. PubMed ID: 12119656 [TBL] [Abstract][Full Text] [Related]
27. A risk-benefit assessment of anti-obesity drugs. Kolanowski J Drug Saf; 1999 Feb; 20(2):119-31. PubMed ID: 10082070 [TBL] [Abstract][Full Text] [Related]
28. [The pharmacological treatment of obesity: past, present and future]. Simonyi G; Pados G; Medvegy M; Bedros JR Orv Hetil; 2012 Mar; 153(10):363-73. PubMed ID: 22370224 [TBL] [Abstract][Full Text] [Related]
29. Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options. Fujioka K Obes Res; 2002 Dec; 10 Suppl 2():116S-123S. PubMed ID: 12490660 [TBL] [Abstract][Full Text] [Related]
30. The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. Rodrigues AM; Radominski RB; Suplicy Hde L; De Almeida SM; Niclewicz PA; Boguszewski CL J Clin Endocrinol Metab; 2002 Apr; 87(4):1621-6. PubMed ID: 11932292 [TBL] [Abstract][Full Text] [Related]
31. Challenges in obesity management. Poston WS; Foreyt JP; Borrell L; Haddock CK South Med J; 1998 Aug; 91(8):710-20. PubMed ID: 9715214 [TBL] [Abstract][Full Text] [Related]
32. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Finer N; Ryan DH; Renz CL; Hewkin AC Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525 [TBL] [Abstract][Full Text] [Related]
33. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. Van Gaal LF; Wauters MA; De Leeuw IH Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480 [TBL] [Abstract][Full Text] [Related]
34. [Drug therapy of obesity]. Wechsler JG Acta Med Austriaca; 1998; 25(4-5):138-41. PubMed ID: 9879389 [TBL] [Abstract][Full Text] [Related]
36. Croatian experience with sibutramine in the treatment of obesity--multicenter prospective study. Stimac D; Ruzić A; Majanović SK Coll Antropol; 2004 Jun; 28(1):215-21. PubMed ID: 15636078 [TBL] [Abstract][Full Text] [Related]
37. Safety of antiobesity drugs. Cheung BM; Cheung TT; Samaranayake NR Ther Adv Drug Saf; 2013 Aug; 4(4):171-81. PubMed ID: 25114779 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological treatment of obesity. Past, present, and future. Wangsness M Minn Med; 2000 Nov; 83(11):21-6. PubMed ID: 11126476 [TBL] [Abstract][Full Text] [Related]
39. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure]. Astrup A Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391 [TBL] [Abstract][Full Text] [Related]